Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder.

Conclusions: XR-NTX treatment in smokers with opioid use disorder was associated with a 29% decline in daily cigarette consumption. Together with prior evidence of increased smoking during opioid agonist therapy, our finding suggests a pharmacodynamic interaction between nicotine and opioid systems that could influence treatment choices in this population. Our findings merit confirmation in a prospective controlled study. (NCT02324725 and NCT01587196). PMID: 32379516 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32379516?dopt=Abstract

Source: The American Journal of Drug and Alcohol Abuse - May 6, 2020 Category: Addiction Authors: Wang AL, Shi Z, Elman I, Langleben DD Tags: Am J Drug Alcohol Abuse Source Type: research